Currency In USD
| Previous Close | 0.41 |
| Open | 0.41 |
| Day High | 0.41 |
| Day Low | 0.41 |
| 52-Week High | 17.1 |
| 52-Week Low | 0.31 |
| Volume | 2.05M |
| Average Volume | 264,402 |
| Market Cap | 2.15M |
| PE | -0.18 |
| EPS | -2.25 |
| Moving Average 50 Days | 2.87 |
| Moving Average 200 Days | 8.22 |
| Change | 0 |
Data not available
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
GlobeNewswire Inc.
Nov 24, 2025 12:05 PM GMT
- Intended to Maximize Stakeholder Value Through Structured Process - - Validated SCS Microinjector® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential - - CLS-AX TK
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
GlobeNewswire Inc.
Aug 26, 2025 12:05 PM GMT
- Presentations Highlight the Versatility of Clearside’s SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases - - CLS-AX Trial Designs in Wet AMD and Diabetic Retinopathy to be Featured in Presentation by Dr. Sobha Sivaprasad -
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
GlobeNewswire Inc.
Jul 23, 2025 11:05 AM GMT
- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLO